Unique Pharmacology And Clinical Evidence Supporting The Antidepressant Therapeutic Potential Of Lumateperone

Gretchen L. Snyder,Robert E. Davis,Sophie Dutheil,Joseph P. Hendrick, Lei Zhang,Lawrence P. Wennogle,Andrew Satlin,Monica M. Marcus,Sharon Mates,Kim Vanover,Torgny H. Svensson

BIOLOGICAL PSYCHIATRY（2018）

引用 1|浏览33

暂无评分

摘要

Lumateperone (ITI-007) is a first-in-class investigational agent which simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, currently in clinical development for schizophrenia, bipolar depression and agitation associated with dementia

查看译文

关键词

Rapid Antidepressant, mTOR, Glutamate Receptors, Dopamine D1 Receptors, Dopamine D2 Receptors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要